scispace - formally typeset
A

Annabell Witzke

Researcher at Max Planck Society

Publications -  7
Citations -  288

Annabell Witzke is an academic researcher from Max Planck Society. The author has contributed to research in topics: Peroxisome proliferator-activated receptor & ATPase. The author has an hindex of 6, co-authored 7 publications receiving 253 citations. Previous affiliations of Annabell Witzke include University of Konstanz.

Papers
More filters
Journal ArticleDOI

Amorfrutins are potent antidiabetic dietary natural products

TL;DR: In diet-induced obese and db/db mice, amorfrutin treatment strongly improves insulin resistance and other metabolic and inflammatory parameters without concomitant increase of fat storage or other unwanted side effects such as hepatoxicity.
Journal ArticleDOI

Amorfrutin B is an efficient natural peroxisome proliferator-activated receptor gamma (PPARγ) agonist with potent glucose-lowering properties

TL;DR: In insulin-resistant mice, amorfrutin B considerably improved insulin sensitivity, glucose tolerance and blood lipid variables after several days of treatment, and had no adverse effects on osteoblastogenesis and fluid retention.
Journal ArticleDOI

Biochemical and biophysical characterisation yields insights into the mechanism of a Cd/Zn transporting ATPase purified from the hyperaccumulator plant Thlaspi caerulescens.

TL;DR: Optimisation of the purification protocol, based on binding of the natural C-terminal His-tag of the protein to a Ni-IDA metal affinity column, yielded pure, active TcHMA4 in quantities sufficient for its biochemical and biophysical characterisation with various techniques.
Journal ArticleDOI

Inhibition of the gastric H,K-ATPase by clotrimazole.

TL;DR: It is discovered that the interaction of clotrimazole with the H,K-ATPase introduces a single "dead-end" branch added to the Post-Albers scheme in the E(1) state of the pump that has a significantly enhanced affinity for protons and bind up to two protons even at pH 8.5.
Journal ArticleDOI

Foam cell specific LXRα ligand.

TL;DR: The liver X receptor α (LXRα) is a ligand-dependent nuclear receptor and the major regulator of reverse cholesterol transport in macrophages as mentioned in this paper, which makes it an interesting target for mechanistic study and treatment of atherosclerosis.